Abstract
1221
Objectives Neuroinflammation serves a putative role in the ongoing neuronal loss in neurodegenerative diseases like Parkinson’s (PD), Alzheimer’s dementia (AD), and multiple sclerosis (MS). The aim of this study was to perform initial characterization of 123-I CLINDE, as an imaging biomarker of the peripheral benzodiazepine receptor, reflecting microglial activation, in PD, AD, and MS subjects and controls.
Methods Twenty-one human subjects (controls=7, PD=5, AD=4, MS=5) underwent serial, dynamic SPECT imaging following the bolus injection of 185 MBq 123-I CLINDE. Images were acquired for up to 4 hours post tracer injection with plasma measures of parent compound and metabolite obtained at each imaging time point. Voxel-wise parametric analyses and VOI sampling was performed on the dynamic data set for interrogation of several kinetic modeling approaches implemented in PMOD.
Results Preliminary analyses of parametric maps compared against a normative template demonstrated discreet clusters of subcortical and cortical increases in 123-I CLINDE uptake. Pharmacokinetic analyses of plasma demonstrates the presence of a minor lipophilic metabolite.
Conclusions 123- I CLINDE demonstrates regional localization in PD, AD, and MS brain suggestive of potential utility as an imaging biomarker of neuroinflammation.
- © 2009 by Society of Nuclear Medicine